Clinical use of lentiviral vectors | Leukemia
Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and hemoglobinopathies. These vectors have also been used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. CAR T-cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors. In this review, we discuss several aspects of lentiviral vectors that will be of interest to clinicians, including an overview of lentiviral vector development, the current uses of viral vectors as therapy for primary immunodeficiencies and cancers, large-scale manufacturing of lentiviral vectors, and long-term follow-up of patients treated with gene therapy products.
Download PDF Subjects Gene therapy Immunotherapy Abstract Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficienci
related reading
- Introduction to AAV as a Gene Therapy Vector, Part 2substack.com
- Viral vector platforms within the gene therapy landscape | Signal Transduction and Targeted Therapynature.com
- Understanding Cell + Gene Therapypatienteducation.asgct.org
- Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practicencbi.nlm.nih.gov
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Futurencbi.nlm.nih.gov
- Introduction to AAV as a Gene Therapy Vector, Part 1substack.com
- Lentiviral expression system for the purification of secreted proteins from human cell cultures | BMC Biotechnology | Springer Nature Linkbmcbiotechnol.biomedcentral.com
- Immunotherapy for Cancer - NCIcancer.gov
- RNA Interference–Based Therapy and Its Delivery Systemsncbi.nlm.nih.gov
- Teaching an old dog new tricks: next-generation CAR T cells | British Journal of Cancernature.com
- Hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes in children and adolescentsuptodate.com
- From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cellsncbi.nlm.nih.gov